Navigation Links
KaloBios Announces Fiscal Year 2012 Financial Results

SOUTH SAN FRANCISCO, Calif., March 27, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced financial results for fiscal year 2012.

(Logo:  Financial Highlights ($ in millions, except per share data, unaudited)FY 2012FY 2011Percent ChangeContract Revenue$
.1$   20.3-70%Research & Development Expense24.518.532%General & Administrative Expense5.14.028%GAAP Net Loss(23.5)(2.2)100%+GAAP Net Loss per Share (basic and diluted)$ (11.22)$  (1.15)100%+Cash, cash equivalents and marketable securities$
20.3$   17.814%GAAP net loss for the year ended December 31, 2012 was $23.5 million ($11.22 per share) compared to GAAP net loss of $2.2 million ($1.15 per share) for the year ended December 31, 2011.

Contract Revenue was $6.1 million for the fiscal year 2012 compared to $20.3 million for 2011.  The decrease in contract revenues was due to the completion of all substantive performance obligations related to research support activities under our agreement with Sanofi Pasteur (Sanofi), the vaccines division of Sanofi Group.

Research and Development (R&D) expenses were $24.5 million for the fiscal year 2012 compared to $18.5M in 2011. R&D expense increased during 2012 due to increased clinical trial activity compared with the prior period.  General and administrative (G&A) expenses were $5.1 million for the fiscal year 2012 compared to $4.0M in 2011. G&A expense increased in 2012 due to higher legal, accounting and consulting costs.  We expect operating expenses to continue to increase during 2013 as we further develop our clinical programs and incur expenses associated with being a public company.

As of December 31, 2012, KaloBios had cash, cash equivalents and marketable securities totaling $20.3 million, compared to $17.8 million at December 31, 2011. On a pro-forma basis at December 31, 2012, including the net proceeds of our initial public offering completed in the first quarter of 2013, the cash, cash equivalent and marketable securities was approximately $83.8M. 

"KaloBios ended 2012 with a strong, differentiated clinical pipeline marked by three first-in-class, patient-targeted therapies for severe asthma, Pseudomonas infections associated with cystic fibrosis and pneumonia, and hematologic malignancies," said David Pritchard, KaloBios' President and Chief Executive Officer. "We continue to move forward aggressively to complete enrollment in the ongoing Phase 2 KB003 asthma study, our Phase 2 KB001-A cystic fibrosis (CF) study and our Phase 1 KB004 hematologic malignancy study."

Anticipated Upcoming Milestones for 2013-20142Q 2013:

File for Orphan Drug Status in the USA and European Union for KB001-A in CF3Q 2013:

Full recruitment of the KB003 asthma study3Q 2013:

Initiation of the expansion phase of the KB004 study in AML with EphA3 diagnostic test4Q 2013:

Full recruitment of the KB001-A CF study 1Q 2014:

Initiation of Phase 2 KB004 study in at least one new indication 1Q 2014:

Top line KB003 Phase 2 asthma study results2Q 2014:

Top line KB001-A CF study results3Q/4Q 2014:

Initiation of Sanofi Phase 2b study for prevention of ventilator-associated pneumonia (VAP) 4Q 2014:

Completion of enrollment in at least one hematologic malignancy indication in the expansion phase of KB004 About KaloBiosKaloBios Pharmaceuticals, Inc. is developing a portfolio of proprietary, patient-targeted, first-in-class monoclonal antibodies (mAbs) designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases.

Currently, KaloBios has three drug development programs:

  • KB003, an anti-GM-CSF mAb with potential to treat inflammatory diseases, is being developed for the treatment of severe asthma and is currently enrolling patients in a 150 patient Phase 2 study in the United States, Europe and Australia.
  • KB001-A, an anti-PcrV mAb fragment, is partnered exclusively with Sanofi and is being developed for the prevention and treatment of Pseudomonas aeruginosa (Pa) infection. KaloBios has retained rights for the cystic fibrosis (CF) indication and has initiated a 180 patient Phase 2 study in CF subjects with chronic Pa infection in the United States. Sanofi is pursuing a ventilator associated pneumonia prevention indication in the intensive care setting.
  • KB004, an anti-EphA3 mAb, has potential in treating hematologic malignancies and solid tumors. KaloBios is currently testing this drug in a Phase 1 study in subjects with hematologic malignancies.
  • All of the company's antibodies were generated using its proprietary Humaneered® technology, a method that converts nonhuman antibodies (typically mouse) into recombinant antibodies that have a high binding affinity to their target and are designed for chronic therapeutic use. The company believes that antibodies produced using its Humaneered® technology offer important clinical and economic advantages over antibodies generated by other methods in terms of high binding affinity, high manufacturing yields, and minimal to no immunogenicity (inappropriate immune response) upon repeat administration in humans.

    For more information on KaloBios Pharmaceuticals, please visit our web site at

    Safe Harbor StatementThis release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including: statements related to our 2013 operating expenses; the statements under the heading "Anticipated Upcoming Milestones for 2013-2014"; and statements regarding the company's clinical development of KB001-A, KB003 and KB004. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the company's limited cash reserves and its ability to obtain additional capital on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that  the company has initiated or plans to initiate; the company's dependence on Sanofi Pasteur for the development and commercialization of KB001-A; the company's ability to successfully complete further development of its programs; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; the company's ability to protect the company's intellectual property; competition; changes in the regulatory landscape or the imposition of regulations that affect the company's products; and other factors listed under "Risk Factors" in the company's Form S-1 filed with the Securities and Exchange Commission on January 30, 2013 and the company's other filings with the Securities and Exchange Commission.

    All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company has no obligation, and expressly disclaims any obligation to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact:Jeffrey H. Cooper
    Chief Financial Officer
    KaloBios Pharmaceuticals, Inc.
    (650) 243-3146

    Media Contact:Joan E. Kureczka
    Kureczka/Martin Associates
    Tel:  (415) 821-2413
    Mobile: (415) 690-0210

    ---- Tables to Follow --Consolidated Balance SheetsDecember 31, 2012 and 2011(in thousands, except share and per share information)December 31,December 31,20122011 (Unaudited)AssetsCurrent assets:Cash and cash equivalents 

    3,338Marketable securities 

    9,35114,509Contract receivables 

    87177Prepaid expenses and other current assets 

    871580Total current assets 

    21,25618,604Restricted cash 

    205205Property and equipment, net 

    230427Deferred offering costs

    2,803-Intangible and other assets 

    45111Total assets 

    9,347Liabilities, convertible preferred stock and stockholders' deficitCurrent liabilities:Accounts payable 

    266Accrued compensation 

    628832Deferred revenue, short-term 

    -5,630Deferred rent, short-term 

    10153Accrued research and clinical liabilities 

    3,5381,079Other accrued liabilities 

    502248Total current liabilities 

    7,2178,108Deferred rent, long-term 

    62163Notes payable

    9,826-Other liabilities, long-term 

    355243Total liabilities 

    17,4608,514Convertible preferred stock, $0.001 par value: 60,152,555 shares and 39,108,536 shares authorized at December 31, 2012, and 2011, respectively; 12,329,330 shares and 10,657,030 shares issued and outstanding at December 31, 2012, and 2011, respectively; aggregate liquidation preference of $105,512 at December 31, 2012

    102,02383,178Stockholders' deficit: Common stock, $0.001 par value: 80,000,000 shares  60,000,000 shares authorized at December 31, 2012, and 2011, respectively; 2,186,695 and 1,986,431 shares issued and outstanding at December 31, 2012, and 2011, respectively

    22Additional paid-in capital 

    3,3172,412Accumulated other comprehensive income (loss) 

    4(1)Accumulated deficit 

    (98,267)(74,758)Total stockholders' deficit 

    (94,944)(72,345)Total liabilities, convertible preferred stock and stockholders' deficit 

    9,347Consolidated Statements of OperationsYear Ended December 31, 2012 and 2011(in thousands, except share and per share information)(Unaudited)Year Ended December 31,20122011Contract revenue$
    ,098$   20,255Operating expenses:Research and development24,51918,512General and administrative5,0614,010Total operating expenses29,58022,522Loss from operations(23,482)(2,267)Other income (expense):Interest income (expense), net(140)43Other income (expense), net113(8)Net loss$ (23,509)$   (2,232)Basic and diluted net loss per common share$   (11.22)$
    (1.15)Weighted average common shares outstanding used to calculate basic and diluted net loss per common share2,095,9501,933,672Stock based Compensation ExpenseYear Ended December 31, 2012 and 2011(in thousands)(Unaudited)Total stock-based compensation expense included in the consolidated statements of operations is as follows:Year Ended December 31,20122011Research and development$
    28General and administrative42393Total stock-based compensation expense$

    SOURCE KaloBios Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. CfPIE Announces Advisory Board to Support Continued Life Sciences Training Alignment with Industry Regulations
    2. SoundConnect Announces Audio Conferencing Capacity Upgrades
    3. BMI Surplus Announces Sale of Thermal Vacuum Space Simulation Chamber
    4. XBiotech Announces Incorporation Of Its Wholly Owned Subsidiary XBiotech Japan KK
    5. National Brain Tumor Society Announces Launch of Defeat GBM Research Collaborative
    6. Regenerative Medicine Company, Eqalix, Announces Grant from Nanotechnology Institute in Philadelphia, Pennsylvania
    7. Probiotics Are in More Than Just Yogurt: Probiotic Action Announces 5 New Items Containing the Healthy Bacteria
    8. Synedgen Announces Issuance of Patent to Optimize Animal Health
    9. Piramal Imaging Announces the Acceptance for Review of [18F] florbetaben by the FDA and EMA for the Visual Detection of beta-amyloid in Alzheimers Disease
    10. Probiotic Action Announces Probiotics Pending Listing on EU Foods
    11. Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
    Post Your Comments:
    (Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik Family ... and six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. ... and administered by the New York Academy of Sciences to honor the excellence ...
    (Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global contract ... to improve patient outcomes and quality of life, will now be offering its ... attributed to new regulatory requirements for all new drug products, including the finalization ...
    (Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
    (Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017  SkylineDx ... London (ICR) and University of Leeds ... to risk-stratify patients with multiple myeloma (MM), in a multi-centric ... The University of Leeds is the ... UK, and ICR will perform the testing services to include ...
    Breaking Biology Technology:
    (Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
    (Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at . 2016 ...
    (Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
    Breaking Biology News(10 mins):